| 梁秋艳,韩 昱,陈立新,李爱娜,李威娜.消栓肠溶胶囊联合依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的临床研究[J].现代生物医学进展英文版,2024,(5):971-974. |
| 消栓肠溶胶囊联合依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的临床研究 |
| Clinical Study on Xiaoshuan Enteric Coated Capsules Combined with Edaravone Dextrorphan Injection Concentrated Solution in Treatment of Acute Cerebral Infarction |
| Received:July 23, 2023 Revised:August 26, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.05.031 |
| 中文关键词: 消栓肠溶胶囊 依达拉奉右莰醇注射用浓溶液 急性脑梗死 疗效 |
| 英文关键词: Xiaoshuan enteric coated capsules Edaravone dextrorphan injection concentrated solution Acute cerebral infarction Curative effect |
| 基金项目:辽宁省科技厅重点研发计划指导计划项目（2018225071） |
|
| Hits: 292 |
| Download times: 242 |
| 中文摘要: |
| 摘要 目的：研究消栓肠溶胶囊联合依达拉奉右莰醇注射用浓溶液治疗急性脑梗死（ACI）的临床疗效。方法：选取2021年3月-2022年8月间我院诊治的132例ACI患者，按照随机数字表法将患者分为对照组（n=66，依达拉奉右莰醇注射用浓溶液治疗）和观察组（n=66，对照组的基础上接受消栓肠溶胶囊治疗）。治疗14d后，对比两组疗效、卒中量表评分[美国国立卫生研究院卒中量表（NIHSS）、改良Rankin评分量表（mRS）]、脑血流灌注指标[平均流速（TMV）、收缩期峰值流速（PSV）、阻力指数（RI）]、炎症因子水平[正五聚蛋白3（PTX-3）、脂蛋白相关磷脂酶A2（Lp-PLA2）、淀粉样蛋白A（SAA）]水平和血管内皮功能指标[一氧化氮（NO）、内皮素-1（ET-1）、血浆血栓素B2（TXB2）]，同时记录两组不良反应发生情况。结果：观察组的临床总有效率高于对照组（P<0.05）。与对照组治疗14 d后相比，观察组的NIHSS、mRS评分、RI、Lp-PLA2、PTX-3、SAA、ET-1、TXB2更低，TMV、PSV、NO更高（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：依达拉奉右莰醇注射用浓溶液和消栓肠溶胶囊联合治疗ACI，可减轻神经损伤，抑制炎症反应，改善血管内皮功能，促进脑循环恢复，且无明显不良反应。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical efficacy of xiaoshuan enteric coated capsules combined with edaravone dextrorphan injection concentrated solution in treatment of acute cerebral infarction (ACI). Methods: 132 ACI patients who were diagnosed and treated in our hospital from March 2021 to August 2022 were selected as research objects, patients were divided into control group (n=66, edaravone dextrorphan injection concentrated solution) and observation group (n=66, xiaoshuan enteric coated capsules on the basis of control group) according to the random number table method. 14d after treatment, the efficacy, stroke scale scores [National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS)], cerebral blood perfusion indexes [mean flow velocity (TMV), peak systolic velocity (PSV), resistance index (RI)], levels of inflammatory factors [lipoprotein-associated phospholipase A2 (Lp-PLA2), pentraxin 3 (PTX-3) and amyloid A (SAA)] and vascular endothelial function indexes [nitric oxide (NO), endothelin-1 (ET-1), plasma thromboxane B2 (TXB2)] were compared between two groups, and the adverse reactions of two groups were recorded. Results: The total clinical effective rate of the observation group was higher than that of the control group (P<0.05). Compared with the control group 14 d after treatment, the observation group had lower NIHSS, mRS scores, RI, Lp-PLA2, PTX-3, SAA, ET-1, TXB2, and higher TMV, PSV, and NO (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of concentrated solution of Edaravone and dextranol for injection and Xiaoshuan enteric coated capsule in the treatment of ACI can reduce nerve injury, inhibit inflammatory reaction, improve vascular endothelial function, and promote the recovery of cerebral circulation without obvious adverse reactions. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
